Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

In an effort to maximize the earnings potential of its plaque psoriasis cream, Danish dermatology biotech MC2 Therapeutics ...

Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has ...

Less than a year after garnering the first anti-CLDN18.2 approval in the U.S., Astellas Pharma is not resting on its laurels.

Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with ...

Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and ...

But on Wednesday, May 28 Moderna revealed the HHS has terminated the award for late-stage development and right to purchase ...

Instead, Stealth submitted a new drug application seeking approval of elamipretide, and the FDA issued its refusal-to-file ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

Siemens Healthineers has deployed its first mobile stroke unit in the U.S., with an ambulance equipped with its own CT ...